newsfilter
← Latest News
GlobeNewswire·

Syndax Reports Second Quarter 2026 Financial Results and Provides Business Update

– Total revenue of $73 million in 2Q26, a 92% year-over-year increase – – Revuforj® (revumenib) net revenue of $54.7 million in 2Q26, a 91% year-over-year increase – – Niktimvo™ (axatilimab-csfr) net revenue of $60.3